OP15
Anti-c-ErbB2/c-Neu (Ab-3) Mouse mAb (3B5)
liquid, clone 3B5, Calbiochem®
別名:
Anti-HER2, Anti-c-Neu, Anti-ErbB2, Anti-Erythroblastosis Virus
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
NACRES:
NA.43
UNSPSC Code:
12352203
Clone:
3B5, monoclonal
Species reactivity:
human, mouse
Application:
—
Citations:
38
biological source
mouse
antibody form
purified antibody
antibody product type
primary antibodies
clone
3B5, monoclonal
form
liquid
contains
≤0.1% sodium azide as preservative
species reactivity
human, mouse
manufacturer/tradename
Calbiochem®
storage condition
do not freeze
dilution
(Frozen Sections (2.5 µg/mL)
Immunoblotting (2-3 µg/mL,
Immunofluorescence (2.5 µg/mL)
Immunoprecipitation (1 µg/sample,
Paraffin Sections (2.5 µg/mL, pressure cooker, heat or trypsin pre-treatment required, )
isotype
IgG1
shipped in
wet ice
Quality Level
Gene Information
human ... ERBB2(2064)
target post-translational modification
unmodified
類似した製品をお探しですか？ 訪問 製品比較ガイド
General description
Anti-c-ErbB2/c-Neu (Ab-3), mouse monoclonal, clone 3B5, recognizes the ~185 kDa c-ErbB2/c-Neu protein in HEK293 cells. It is validated for WB, IF, IP, and IHC on frozen and paraffin sections.
Purified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with Sp2/0.Ag14 cells (see application references). Recognizes the ~185 kDa c-Erb2/c-Neu protein.
Recognizes the ~185 kDa c-ErbB2/c-Neu protein in HEK293 cells.
Immunogen
Human
a synthetic peptide (TAENPEYLGLDVPV) corresponding to amino acids 1242-1255 from the C-terminal domain of human c-ErbB2/c-Neu
Application
Frozen Sections (2.5 g/ml)
Immunoblotting (2-3 g/ml, see application references)
Immunofluorescence (2.5 g/ml)
Immunoprecipitation (1 g/sample, see application references)
Paraffin Sections (2.5 g/ml, pressure cooker, heat or trypsin pre-treatment required, see application references)
Packaging
Please refer to vial label for lot-specific concentration.
Physical form
In 0.05 M sodium phosphate buffer, 0.2% gelatin.
Analysis Note
Negative Control
HepG2 cells or normal skin
HepG2 cells or normal skin
Positive Control
SK-BR-3 cells or breast carcinoma tissue
SK-BR-3 cells or breast carcinoma tissue
Other Notes
For paraffin sections, we recommend pre-treating with a pressure cooker, but trypsin and heat will also work well. Including 0.05% saponin during staining of paraffin sections may help reduce background. In one study ductal carcinomas in situ displaying large-cell, comedo growth type, were stained while none of 16 ductal carcinomas in situ of small-cell, papillary, or cribriform growth type were stained by this antibody. Antibody should be titrated for optimal results in individual systems.
Mamcs, J.R., et al. 1994. Ann. Surg.219, 332.
Tetu, B., et al. 1994. Cancer73, 2359.
DiFiore, P.P., et al. 1987. Science237, 178.
Slamon, D.J., et al. 1987. Science235, 177.
Varley, J.M., et al. 1987. Oncogene1, 423.
Bargmann, C.I., et al. 1986. Nature319, 226.
Yamamoto, T., et al. 1986. Nature319, 230.
Blick, M., et al. 1984. Blood64, 1234.
Schwab, M., et al. 1984. Cold Spring Harbor Laboratory 2, 215.
Tetu, B., et al. 1994. Cancer73, 2359.
DiFiore, P.P., et al. 1987. Science237, 178.
Slamon, D.J., et al. 1987. Science235, 177.
Varley, J.M., et al. 1987. Oncogene1, 423.
Bargmann, C.I., et al. 1986. Nature319, 226.
Yamamoto, T., et al. 1986. Nature319, 230.
Blick, M., et al. 1984. Blood64, 1234.
Schwab, M., et al. 1984. Cold Spring Harbor Laboratory 2, 215.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
保管分類
10 - Combustible liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
OP15-ML: + OP15-MG: + OP15-100UG:
jan
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Peter Nagy et al.
Journal of cell science, 115(Pt 22), 4251-4262 (2002-10-12)
The ErbB family of transmembrane receptor tyrosine kinases plays an important role in the pathogenesis of many cancers. The four members of the family, ErbB1-4, form various homo- and heterodimers during the course of signal transduction. A second hierarchical level
Zongming Liu et al.
Scientific reports, 9(1), 622-622 (2019-01-27)
Breast cancer brain metastasis (BCBM) remains a major clinical problem. Approximately 10-16% of patients with breast cancer develop brain metastases (BCBM). However, no systemic therapy has gained regulatory approval for the specific treatment of BCBM and this remains an area
Henriette O'Geen et al.
Epigenetics & chromatin, 12(1), 26-26 (2019-05-06)
Rewriting of the epigenome has risen as a promising alternative to gene editing for precision medicine. In nature, epigenetic silencing can result in complete attenuation of target gene expression over multiple mitotic divisions. However, persistent repression has been difficult to
Yoriko Yamashita-Kashima et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 17(15), 5060-5070 (2011-06-28)
We investigated the antitumor activity of the combination of two different humanized monoclonal human epidermal growth factor receptor (HER) 2 antibodies, pertuzumab and trastuzumab, for gastric cancer. Tumor mouse xenograft models were used to examine antitumor activity. Cell proliferation was
Kristina W Thiel et al.
Nucleic acids research, 40(13), 6319-6337 (2012-04-03)
Human epidermal growth factor receptor 2 (HER2) expression in breast cancer is associated with an aggressive phenotype and poor prognosis, making it an appealing therapeutic target. Trastuzumab, an HER2 antibody-based inhibitor, is currently the leading targeted treatment for HER2(+)-breast cancers.
グローバルトレードアイテム番号
| カタログ番号 | GTIN |
|---|---|
| OP15-100UGCN | 04055977224658 |
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）